NCT07093710View on ClinicalTrials.gov

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or GemOx in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2029

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

Golidocitinib

"Cohort1: 150mg, po, qd;~Cohort2: 150mg, po, qod and 150mg, po, qd (phase Ib); RP2D (II study)"

DRUG

Mitoxantrone Hydrochloride Liposome

Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)

DRUG

GemOx

Cohort 2: Gemcitabine：1g/m2，IV，D1; Oxaliplatin：100mg/m2, IV，D1

All Listed Sponsors
lead

Sun Yat-sen University

OTHER